Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

Journal of Clinical Investigation

Volumn 112, Issue 8, 2003, Pages 1223-1233

  Zhang, Hongbing ^a   Cicchetti, Gregor ^a   Onda, Hiroaki ^a   Koon, Henry B ^b   Asrican, Kirsten ^a   Bajraszewski, Natalia ^a   Vazquez, Francisca ^b   Carpenter, Christopher L ^b   Kwiatkowski, David J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Genetics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYSTADENOMA; DOWN REGULATION; EMBRYO; EMBRYO CELL; ENZYME ACTIVITY; FAMILIAL DISEASE; FIBROBLAST; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; KIDNEY CYST; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR DOWN REGULATION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL AGING; CELLS, CULTURED; DOWN-REGULATION; MALE; MICE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REPRESSOR PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0347988005     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317222     Document Type: Article

References (35)

1. Cheadle, J.P., Reeve, M.P., Sampson, J.R., and Kwiatkowski, D.J. 2000. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107:97-114.
2. Gomez, M., Sampson, J., and Whittemore, V. 1999. The tuberous sclerosis complex. Oxford University Press. Oxford, United Kingdom. 340 pp.
3. Roach, E.S., Gomez, M.R., and Northrup, H. 1998. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol. 13:624-628.
4. Onda, H., Lueck, A., Marks, P.W., Warren, H.B., and Kwiatkowski, D.J. 1999. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104:687-695.
5. Kwiatkowski, D.J., et al. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525-534.
6. Kobayashi, T., et al. 2001. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. U. S. A. 98:8762-8767.
7. Kobayashi, T., et al. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59:1206-1211.
8. Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E., and Hariharan, I.K. 2001. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 105:345-355.
9. Potter, C.J., Huang, H., and Xu, T. 2001. Drosophila TSC1 functions with TSC2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 105:357-368.
10. Gao, X., and Pan, D. 2001. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15:1383-1392.
11. Gao, X., et al. 2002. Tsc tumour suppressor proteins antagonize aminoacid-TOR signalling. Nat. Cell. Biol. 4:699-704.
12. Porter, C.J., Pedraza, L.G., and Xu, T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. 4:658-665.
13. Dan, H.C., et al. 2002. PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277:35364-35370.
14. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:151-162.
15. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 4:648-657.
16. Donehower, L.A., et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:215-221.
17. Peterson, R.T., Desai, B.N., Hardwick, J.S., and Schreiber, S.L. 1999. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc. Natl. Acad. Sci. U. S. A. 96:4438-4442.
18. Tolias, K.F., Cantley, L.C., and Carpenter, C.L. 1995. Rho family GTPases bind to phosphoinositide kinases. J. Biol. Chem. 270:17656-17659.
19. Soucek, T., Yeung, R.S., and Hengstschlager, M. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the sclerosis complex gene-2. Proc. Natl. Acad. Sci. U. S. A. 95:15653-15658.
20. Goncharova, E.A., et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277:30958-30967.
21. Brown, E.J., et al. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:756-758.
22. Brunn, G.J., et al. 1996. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15:5256-5267.
23. Arcaro, A., and Wymann, M.P. 1993. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296:297-301.
24. Ballif, B.A., Shimamura, A., Pae, E., and Blenis, J. 2001. Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent n-alpha-tosyl-1-phenylalanyl chloromethyl ketone. J. Biol. Chem. 276:12466-12475.
25. Duncia, J.V., et al. 1998. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8:2839-2844.
26. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T., and Saltiel, A.R. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
27. Ishihara, H., et al. 1989. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159:871-877.
28. Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., and Chen, J. 2001. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 294:1942-1945.
29. Hara, K., et al. 1998. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BPI through a common effector mechanism. J. Biol. Chem. 273:14484-14494.
30. Bilder, G.E., et al. 1991. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260:C721-C730.
31. van Slegtenhorst, M., et al. 1998. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7:1053-1058.
32. Plank, T.L., Yeung, R.S., and Henske, E.P. 1998. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res. 58:4766-4770.
33. Bertram, P.G., Zeng, C., Thorson, J., Shaw, A.S., and Zheng, X.F.S. 1998. The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr. Biol. 8:1259-1267.
34. Paasinen-Sohns, A., and Holtta, E. 1997. Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression. Oncogene. 15:1953-1966.
35. Fernandez, M., and Eng, C. 2002. The expanding role of PTEN in neoplasia: a molecule for all seasons? Clin. Cancer Res. 8:1695-1698.